BRAF and non-small cell lung carcinoma: Strategies have been developed for the treatment of non-V600E BRAF-variant tumors in cancers such as CRC and NSCLC.29,30 In our study, we found broad differences in drug sensitivity for different BRAF variant classes, such as those between BRAF V600E variants and non-V600E BRAF variants.